Antiangiogenic gene therapy is a promising strategy for cancer treatment, which generally requires highly efficient delivery systems. To date, success of this strategy has depended almost exclusively on the delivery of high titers of viral vectors, which can result in effective transgene expression. However, their cytotoxicity and immunogenicity are a major concern for clinical applications. Recent advances in delivery efficiency of naked DNA could potentially meet the requirement for both high transgene expression and minimal side effects. To investigate whether naked DNA can be used for antiangiogenic cancer therapy, an expression plasmid was generated that encodes a soluble form of fetal liver kinase-1 (Flk-1) gene, a receptor for vascular endothelial growth factor (VEGF). Hydrodynamic injection of this plasmid resulted in close to 0.1 mg/ml of soluble Flk-1 protein in mouse serum and blocked VEGF-driven angiogenesis in matrigel in vivo. The same delivery significantly suppressed the growth of two different pre-existing subcutaneous tumors, Renca renal cell carcinoma and 3LL lung carcinoma. CD31 immunohistochemistry revealed that the tumorassociated angiogenesis was also highly attenuated in soluble Flk-1-treated mice. Thus, expression of genes by hydrodynamicsbased gene delivery of naked DNA appears to be a promising approach for antiangiogenic cancer gene therapy.
Introduction
Targeting tumor angiogenesis is a promising approach for cancer treatment. This is because the growth and progression of tumors depends on successful development of blood vessels to supply the tumor with oxygen and nutrients. 1 Specifically, targeting endothelial cells also provides several additional advantages from a therapeutic standpoint. Whereas genetic instability of tumor cells quite often renders them resistant to chemotherapeutic agents, endothelial cells are genetically stable and less likely to acquire drug resistance. 2 When stimulated by tumor-derived angiogenic factors, endothelial cells in tumor tissue have unique phenotypes that are quite different from quiescent endothelial cells, 3 which could allow selective drug delivery to tumor sites. 4, 5 Approaches to block angiogenesis have been either neutralizing tumor-associated angiogenic factors, 6 ,7 their receptors 8, 9 or the administration of antiangiogenic factors that directly promote apoptosis of endothelial cells or inhibit their migration. 2, 10 In each case, a high concentration of therapeutic reagents needs to be reached, often for a prolonged period, 11 in order to inhibit tumor progression by targeting tumor blood vessels. Hence, some of the most successful antiangiogenic gene therapy relies on viral systems, such as the delivery of recombinant adenovirus 11, 12 or adeno-associated viruses (AAV), 13, 14 both of which facilitate quite efficient transgene expression in vivo. However, there are several drawbacks to the use of viral vectors for clinical use. First, they are often cytotoxic and serious side toxicities have been reported. Secondly, immunogenicity of viral vectors might disable repetitive treatments. Finally, the generation of replication-competent viruses and ineffective process is a concern in manufacturing viral vectors for clinical uses. 15 Naked DNA-mediated gene delivery, on the other hand, often overcomes these disadvantages of viral vectors. The delivery of naked DNA does not pose health risks. Naked DNA itself has low immunogenicity and therefore can be administered repeatedly. Naked DNA is the simplest vector system to manufacture the large qualities required for human treatment, and its quality is easily controlled and can be stored for long periods of time in a lyophilized form. 16 Regardless of these benefits, gene therapy using naked DNA has been limited because of its inefficient delivery and the resulting transient transgene expression. 17 However, the development of hydrodynamics-based gene delivery has dramatically improved in vivo transgene expression of naked DNA. 18, 19 For example, a high concentration of gene products could be achieved in mouse serum by injecting corresponding cytokine genes by the hydrodynamicsbased gene delivery. [20] [21] [22] Shortly after hepatitis virus genome was delivered, replication of virus was observed in mice. 23, 24 Small interfering RNA was also successfully delivered to mice to prevent fulminant hepatitis 25 or acute liver failure. 25, 26 Importantly, several independent studies showed that hydrodynamics-based gene delivery could mediate the safe and efficient delivery of naked DNA to skeletal muscle cells of primates, 27, 28 implying its possible application for human use. This recent progress suggests that hydrodynamics-based gene delivery may be a promising alternative to viral systems to deliver antiangiogenic genes. However, to our knowledge, few studies on antiangiogenic gene therapy using naked DNA have been reported.
As an angiogenic factor, vascular endothelial growth factor (VEGF) is critical for tumor growth and progression and is secreted by tumor cells and surrounding stromal cells. VEGF binds to two functionally different receptors, Flt-1 and fetal liver kinase-1 (Flk-1), both of which belong to the receptor type tyrosine kinase superfamily. It is generally believed that Flk-1 is the main transducer of VEGF signaling, 29, 30 whereas Flt-1 has a much weaker kinase activity and is unable to generate a mitogenic response in endothelial cells in response to VEGF. Flk-1 is expressed specifically in activated endothelial cells, such as tumor tissue or inflammation sites, and Flt-1 expression is observed in several cell types. The selectivity and potency of VEGF in tumor angiogenesis has prompted a number of VEGF-targeted therapeutic strategies, such as monoclonal antibodies against VEGF, 31, 32 and its receptors, 33 soluble forms of VEGF receptor to sequester the ligand from its receptors, 34 small molecules to inhibit VEGF signaling. 35 In addition, recent clinical studies demonstrated a recombinant humanized anti-VEGF antibody, bevacizumab, is effective in patients with renal cell carcinoma 36 and colon cancer. 37, 38 To investigate whether naked DNA can be used for antiangiogenic cancer gene therapy, we employed the hydrodynamics-based gene delivery to treat a well-defined mouse tumor model with a soluble form of Flk-1. Our results show that hydrodynamics-based gene delivery of the Flk-1 naked DNA produces a significantly high concentration of soluble VEGF receptor systemically. This treatment was efficient enough to inhibit VEGFderived matrigel and tumor growth, presumably by blocking tumor angiogenesis and without significant side effects.
Materials and methods

Cell line
The human embryonic kidney cell line, 293, was maintained in Dulbecco's modified Eagle's medium with 10% fetal calf serum (FCS). Human primary endothelial cells isolated from umbilical vein (HUVEC) were from ATCC (Manassas, VA) and cultured in M199 medium containing 20% FCS, 100 mg/ml endothelial cell growth factor (Pharmacia, Piccadilly, NJ) and 100 mg/ml heparin (Sigma, St Louis, MO). Renca mouse renal cell carcinoma was passed in Balb/c mice or was cultured in Roswell Park Memorial Institute (RPMI) 1640 containing 10% fetal bovine serum, 10 mM sodium pyruvate, 2 mM L-glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin. 3LL lung carcinoma is maintained with the same conditioned medium for 293 cells.
Construction of pFlk-hFc transfection and Western blotting
The murine Flk-1 cDNA (nucleotide number 208-2400 of Genbank accession number NM_010612) was amplified by reverse transcription polymerase chain reaction using total RNA from in vivo growing Renca tumor. pFc control vector was generated using constant region (Fc) of human immunoglobulin 1 (IgG1) cDNA with mouse interleukin-12 p40 signal sequence (nucleotide number 35-133 of Genbank accession number M86671) at the 5 0 site of Fc to facilitate secretion. 1 Â 10 6 293 cells were transfected with 1 mg of the pFlk-hFc plasmid DNA in a six-well plate using Fugene-6 (Roche Applied Science, Indianapolis, IN). The supernatant of the transfection was analyzed by Western blotting using anti-mouse Flk-1 (R&D Systems, Minneapolis, MN), horseradish peroxidase-conjugated anti-mouse Fc (Sigma) monoclonal antibodies and SuperSignal WestPico chemiluminescent substrate (Pierce, Rockford, IN).
Enzyme-linked immunosorbent assay
Production of mouse VEGF was measured using a mouse VEGF enzyme-linked immunosorbent assay (ELISA) Kit (R&D Systems). The concentration of Flk-hFc was determined by sandwich ELISA with anti-murine Flk-1 as the capture antibody (R&D Systems) and anti-human IgG1 Fc-horseradish peroxidase as the detection antibody (Jackson ImmunoResearch, West Grove, PA). Color was developed by 3,3 0 ,5,5 0 -tetramethylbenzidine substrate (KPL, Gaithersburg, MD) and its stop solution (KPL).
Proliferation and chemotaxis assay of HUVEC
To determine the proliferation of endothelial cells, HUVEC were plated at 3 Â 10 3 cells per well in 96-well plates with 10% FCS M199. Twenty-four hours later, the culture medium was replaced with M199 10% FCS, 100 mg/ml heparin, 100 ng/ml mouse VEGF and 20% v/v of the test sample in a total volume of 200 ml. Seventy-two hours later, cell viability was measured 3 h after the addition of WST-1 (Roche), by measuring OD 410 as test and OD 630 as reference.
Migration assays were performed in a modified Boyden Chamber using a 48-well chemotaxis chamber (Neuro Probe Inc., Gaithersburg, MD). Eight-micron nucleopore polyvinylpyrrolidine-free polycarbonate filters (Neuro Probe, Inc.) were coated with 100 mg/ml of collagen type I (Sigma). The filter was placed over the lower chamber containing testing reagents in RPMI 1640 medium with 1% bovine serum albumin, Fraction V (Sigma). HUVEC were suspended in RPMI 1640 medium, and 1 Â 10 4 cells in 50 ml were added to each well in the upper chamber. The assembled chemotaxis chamber was incubated for 6 h at 371C with 5% CO 2 to allow cells to migrate through the collagen-coated polycarbonate filter. Non-migrated cells on the upper surface of the filter were removed, and migration was quantified by counting the migrated cells in three random high-powered fields ( Â 200 total magnification) per filter.
Mice
Female Balb/c and C57 BL/6 mice were obtained from the Animal Production Area, National Cancer Institute at Frederick. The mice were used at 8-10 weeks of age and weighed 20-25 g at the time experiments were initiated.
In vivo gene delivery by hydrodynamics-based gene delivery Plasmid DNA was prepared using an Endofree Maxi or Mega Kit (Qiagen, Valencia, CA). The genes were delivered to the mice by the hydrodynamics-based technique. [39] [40] [41] In brief, using a 27-gauge needle, 10 mg of plasmid DNA in 1.6 ml of 0.9% NaCl was injected through the tail vein of the mice in approximately 5 s.
In vivo matrigel plug angiogenesis assay Matrigel (200 ml; Beckton Dickinson Labware, Bedford, MA) containing 100 ng/ml of mouse VEGF was injected subcutaneously into the flank of Balb/c mice. At the end of the assay, the vascularity of the plug was quantitated by injecting 1% fluorescein isothiocyanate (FITC)-Dextran (molecular weight 200 kDa; Sigma) into the mice as described previously, 42 with some modifications. Twenty minutes after intravenous FITC-Dextran injection, the plug was harvested, weighed and solubilized in 500 ml of dispase (Beckton Dickinson Labware) at 371C for 60 min. Fluorescence in the matrigel was measured using CytoFlur (PerSeptive Biosystems, Framingham, MA) and angiogenesis in the matrigel was evaluated relative to the value of VEGF-containing matrigel without treatment.
Tumor treatment 2 Â 10 5 Renca cells or 1 Â 10 6 3LL cells were injected subcutaneously into the flank of Balb/c or C57/B6 mice, respectively. Three days later, 10 mg of plasmid DNA in 1.6 ml of 0.9% NaCl was injected intravenously, using hydrodynamics-based gene delivery. Tumor size was defined as the product of two perpendicular diameters as follows: (longer diameter) Â (shorter diameter). 2 
Immunohistochemistry
Tissues were either fixed in zinc fixative or snap frozen in 22-oxacalcitriol and stained using anti-mouse CD31 (BD Pharmingen, San Jose, CA; diluted to 1:100), VECTAS-TAIN Elite ABC Kit and DAB Substrate Kit (Vector Laboratories, Burlingame, CA) or HistoMouse Kit (Invitrogen, Carlsbad, CA).
Statistical analysis
Statistical analysis was performed by Prism software (GraphPad Software Inc., San Diego, CA), using the Mann-Whitney U-test, unpaired t-test or two-way analysis of variance (ANOVA). A P-value below 0.05 was considered a significant difference.
Results
Construction and characterization of a soluble VEGF receptor-2-human Fc fusion vector, pFlk-hFc
As an antiangiogenic gene to block VEGF activities, a mammalian expression vector encoding a fusion protein of the extracellular domain of Flk-1 (VEGF receptor-2) and human IgG1 Fc was constructed and designated as pFlk-hFc (Figure 1a ). When pFlk-Fc was transiently transfected into 293 cells, a protein of the expected size was detected in the supernatant by Western blotting using antibodies that recognize the corresponding extracellular domain of the VEGF receptor (Figure 1b) . Probing the same blot with anti-human IgG1 Fc antibody disclosed reactivity at the same molecular weight. In both experiments, no bands were observed in supernatants from transfection control, green fluorescent protein gene (Figure 1b) . These data showed that pFlk-hFc produces soluble Flk-1 fusion protein. The same supernatants were tested for their ability to inhibit HUVEC proliferation in the presence of 10 ng/ml of murine VEGF 165 . The pFlkhFc transfection supernatants inhibited up to 50% of the HUVEC proliferation in a dose-dependent manner (Figure 1c ). This transfection supernatant also inhibited HUVEC chemotaxis induced by 1 or 10 ng/ml of mouse VEGF. In this setting, the pFlk-hFc supernatants blocked up to 78% of the migration of HUVEC (Figure 1d ). Inhibition was more pronounced when chemotaxis was induced by 1 ng/ml of VEGF than when 10 ng/ml was used. These studies suggest that the pFlk-hFc encodes a soluble Flk-1 protein that neutralizes VEGF function.
Pharmacokinetics of pFlk-hFc gene products after hydrodynamics-based gene delivery The pFlk-Fc plasmid constructed above was then delivered to Balb/c mice by hydrodynamics-based gene delivery to determine the pharmacokinetics of its gene product, Flk-Fc. The production of Flk-Fc in the mouse serum was the highest (94 mg/ml) at 24 h after injection of pFlk-Fc (Figure 2a) . The levels of gene product in the serum gradually decreased to several hundred pg/ml over 10 days, without further substantial decrease over 28 days. Although considerable amounts of the gene product were maintained in the serum after a single injection, we investigated whether additional injection could further restore protein expression to the initial peak levels. A second injection of the pFlk-Fc on day 7 induced another peak of protein expression that was comparable in magnitude to the initial injection (Figure 2b ). The mice remained quite healthy for the full duration of the study, regardless of the presence of persistently high concentrations of soluble VEGF receptors in the serum. These results showed that hydrodynamics-based delivery of pFlk-Fc produces highly efficient expression in mice without apparent side effects.
Inhibition of VEGF-induced angiogenesis in matrigel by hydrodynamics-based gene delivery of pFlk-hFc As high amount of Flk-Fc was produced systemically in mice by hydrodynamics-based gene delivery, in vivo antiangiogenic activity of the pFlk-Fc was evaluated using matrigel plugs containing VEGF. As shown in Figure 3 , approximately 50% less blood vessels were present in the matrigel when mice were treated with the pFlk-hFc gene. This result suggests that the serum concentration of Flk-Fc achieved by the corresponding gene delivery is high enough to block VEGF-stimulated angiogenesis.
Inhibition of subcutaneous tumor growth by hydrodynamics-based gene delivery of pFlk-Fc A strategy to block tumor-associated angiogenesis has been one of the most promising therapeutics for cancer. Because of potent antiangiogenic activities by delivery of pFlk-Fc plasmid as shown above, the same treatment was applied to tumor-bearing mice to evaluate its antitumor efficacy. As the target of this therapy is VEGF, we Hydrodynamics-based gene delivery to suppresses the growth of tumors H Yazawa et al measured the production of VEGF by various tumors. The highest amount of VEGF was detected in the medium of Renca murine renal cell carcinoma (2300 ng/ml), followed by CT-26 murine colon cancer (855 ng/ml) and 3LL murine lung carcinoma (420 ng/ml) ( Figure 4a ). We chose Renca and 3LL tumors as our tumor models for pFlk-Fc therapy as high and intermediate VEGF producer, respectively. Initial studies showed that a single injection of pFlk-Fc was not sufficient to inhibit the progressive growth of Renca when treatment was started 3 days after tumor implantation (data not shown). However, as a second injection of the pFlk-Fc vector produced another peak in soluble VEGFR expression when it was given 7 days after the first DNA delivery (Figure 2b ), hydrodynamics-based gene delivery was repeated on day 10 ( Figure 4b ). This two-injection regimen successfully inhibited tumor growth by 70% in the pFlk-hFc-treated group when compared to control treatments at day 21. The growth of 3LL tumors was also suppressed by pFlk-Fc delivery by 64% (Figure 4c ). The median sizes of tumors in the pFlk-hFc-treated and -untreated groups were 625 and 2121 mm 3 in Rencabearing mice and 183 and 512 mm 3 in 3LL-bearing mice, respectively. Overall, these data suggest that hydrodynamics-based gene delivery of pFlk-Fc has a significant impact on the growth of tumors in vivo; that the antitumor effect was dose-dependent; and that a maximal concentration of fusion protein during the first 10 days after DNA injection was needed to effectively restrain tumor growth.
Inhibition of tumor angiogenesis by hydrodynamicsbased gene delivery of pFlk-Fc
Hydrodynamics-based delivery of pFlk-hFc also effectively antagonized VEGF-driven angiogenesis in matrigel implants. However, as often reported, tumor angiogenesis can be multifactorial, 43, 44 with VEGF presumably playing a major, but not exclusive, role in tumor-associated angiogenesis. Thus, vascular density of subcutaneous tumors was investigated to verify that inhibition of tumor growth is consistent with the antiangiogenic activities of these soluble VEGF receptors. In the Renca tumor, CD31 immunostaining showed that although microvessels were observed at high density within the tumor tissues in nonor control vector treatment groups (Figure 5a ), the Renca tumor was 50% less vascularized in the pFlk-hFc-treated group (Figure 5c ). In contrast, fewer blood vessels were observed within untreated 3LL tumor tissues (Figure 5b) . Interestingly, active angiogenesis was observed at the peritumoral space of the 3LL tumor in untreated and control vector-treated groups and was significantly suppressed by hydrodynamic-based delivery of pFlk-Fc (Figure 5b and d) .
These results demonstrate that hydrodynamics-based delivery of the soluble VEGF receptor gene effectively suppresses pre-existing subcutaneous tumor growth by suppressing tumor angiogenesis.
Discussion
To promote angiogenesis, intramuscular injection of naked DNA encoding VEGF has been clinically used for vascular defects caused by cardiovascular disease 45 or peripheral artery disease. 46 These studies prove that delivery of naked DNA can be safely applied to human use although it has limited applications, because of relatively low transgene expression efficiency. On the other hand, the goal of blocking angiogenesis with naked DNA is challenging, because of the requirement for a much higher dose of antiangiogenic gene product. Therefore, the current study demonstrates the important finding that a hydrodynamics-based delivery of naked DNA encoding soluble Flk-1 effectively suppresses the growth of pre-existing tumor. The therapeutic DNA was delivered without significant side effects. The demanding feature of antiangiogenic gene therapy was illustrated by the fact that single injection of pFlk-Fc was not sufficient to inhibit the tumor growth, regardless of the fact that the gene product was detected in mouse serum for almost 1 month post DNA injection.
Although a few reports demonstrate impressive effects against pre-existing tumors by intravenous Flk-1 Hydrodynamics-based gene delivery to suppresses the growth of tumors H Yazawa et al adenovirus to date, the majority of antiangiogenic gene therapy using soluble forms of VEGFRs have had limited success in mouse tumor models. Kong et al. 47 have shown that adenovirus vector-encoded Flt-1 (VEGFR-1)-suppressed tumor growth when delivered locally but not systemically. Takayama et al. 12 have reported systemic antitumor efficacy of adenovirus Flt-1, but only against coinjected and not pre-existing tumor burdens. In this latter case, the inability to observe significant activity against pre-existing tumors may have resulted from insufficient production of gene products. AAV facilitates high and long-lasting transgene expression, which are desirable characteristics for successful antiangiogenic gene therapy. However, it took at least 2 months after the injection for the AAV encoding Flk-1 to reach maximal levels (60 mg/ml) of its gene product and this peak was maintained for 25 weeks. 13 We detected somewhat higher amounts of Flk-1 protein within 24 h after hydrodynamics-based gene delivery of pFlk-Fc naked DNA, although the expression dropped rapidly after this peak. With naked DNA, the therapeutic concentration of Flk-Fc appears to be maintained by adding a second DNA injection within 1 week.
In studies that treat established tumors with antibodyblocking VEGF or its receptor, large quantities of reagents were required. For example, 800 mg/ml of antiantibody Flk-1 was needed to treat tumor-bearing mice every 3 days. 48 Colon cancer patients have been treated with 5 mg/kg of bevacizumab, an anti-VEGF monoclonal antibody, every 2 weeks in phase II studies. 49 Considering the important differences in pharmacokinetics of naked DNA from adenovirus or AAV and its ease of production at low cost, delivery of naked DNA appears to offer quite unique options for future antiangiogenic cancer treatments.
Naked DNA has been often safely injected by the conventional method (e.g., injection of DNA with 200 ml of vehicle to mice) but hydrodynamics-based gene delivery may appear harsh as DNA in a large volume (up to 10% of body weight) is injected into mice quickly. Indeed, within 24 h after the DNA injection, mouse serum alanine aminotransferase rose to about 1000 IU/ml, 18 but this parameter rapidly returned to the normal range (30 IU/ml) within several days. Recent mechanistic studies indeed suggest that plasmid DNA can be safely delivered by hydrodynamics-based gene delivery and that this technique could be amenable for human use. In hydrodynamics-based gene delivery, injected DNA was expressed mainly in the liver and 10-15% of hepatocytes were transfected following the administration of 10 mg of DNA. 50 The hydrodynamics-based injection induces a transient and a sharp increase in venous pressure. These changes eventually cause enlargement of liver fenestrae, small pores seen in less than 10% of the surface area of liver capillary, allowing DNA to go through the capillary and to reach the surfaces of the hepatocytes. 51 The hydropressure also enhances membrane permeability of the hepatocytes and plasmid DNA to enter the intracellular space. 51 This suggests that the delivery is not necessarily DNA-specific. Indeed, molecules such as Evans blue or b-galactosidase protein were also effectively delivered to mouse liver by the same approach. 51 In addition, Hydrodynamics-based gene delivery to suppresses the growth of tumors H Yazawa et al propidium iodiode was effectively incorporated by liver cells following hydrodynamics-based delivery, and at the same time previously expressed green fluorescent protein was dramatically eliminated from the liver. 52 Interestingly, a prior large-volume injection of DNA allows effective transgene expression from a second plasmid that is subsequently delivered in normal volume (0.2 ml) as long as the second DNA is injected within 5 min of the first injection. 52 These results suggest that hepatocytes might be more permeable for a short period of time after the injection. The elevation of transaminases can be explained by release of these enzymes from viable cells not necessarily released from damaged cells. This theory was also supported by the histological studies showing less than 1% of necrotic cells were observed a day after the hydrodynamics-based injections. 53 Using hydrodynamics-based gene delivery, naked DNA has been expressed not only in mouse liver but also in other organs of larger animals. Intra-arterial 28, 54 or intravenous 27 injection of naked DNA resulted in very effective gene expression in limb muscles of mice, dogs and monkeys when this technique was applied with a tourniquet or blood pressure cuff. Hydro-pressure was also created in rabbit liver using a balloon occlusion balloon catheter at the individual hepatic vein or inferior vena cava for efficient transgene expression. 55 These findings might encourage further exploitation of hydrodynamics-based gene delivery for future human use.
Histological examination of tumor tissues disclosed that the majority of anti-VEGF 11, 12 or other antiangiogenic therapies 56, 57 appears to inhibit development of intratumoral microvessels. Therefore, it is intriguing that the anti-VEGF therapy by pFlk-Fc suppressed peritumoral angiogenesis of the 3LL tumor, whereas the intratumoral angiogenesis did not change after the therapy. Consistent with our results, in the C6 glioma model, synthetic Flk-1 inhibitor SU5614 blocked angiogenesis better in peritumoral blood vessels than in the intratumoral area. 58 Kusters et al. 59 showed that expression of 121-VEGF-A isoform in human melanoma predominantly led to peritumoral vessels in mice. Thus, our current study, along with the other studies, suggests that the angiogenesis is induced by tumor cells with different mechanisms involving various factors. Although the same pFlk-Fc delivery similarly inhibited the growth of different tumors in our study, distinct angiogenic molecular pathway(s) appears to be blocked in each model.
In conclusion, this study is a proof of principle that naked DNA, with all the benefits discussed here, can be an excellent candidate for challenging antiangiogenic cancer gene therapy when it is delivered by the hydrodynamics-based method.
